Empirico develops a platform that utilizes human genetic data to create siRNA-based therapies that replicate beneficial genetic variants associated with improved health outcomes. The company focuses on addressing unmet medical needs by advancing a pipeline of differentiated clinical and preclinical programs for common diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many common diseases lack effective treatments due to incomplete understanding of the underlying biological mechanisms and a lack of drug targets validated by human genetics. Traditional drug discovery approaches often fail to translate preclinical findings into successful clinical outcomes.
Solution
Empirico leverages human genetic data to identify and validate novel drug targets, focusing on targets that mimic the effects of naturally occurring genetic variants associated with improved health outcomes. The company develops siRNA-based therapies and explores other modalities to create precision medicines that address the root causes of disease. By focusing on genetically validated targets, Empirico aims to increase the probability of success in clinical development and deliver differentiated therapies for common diseases with unmet medical needs.
Target Audience
Empirico's primary focus is on patients suffering from common diseases with unmet medical needs, and their therapies are designed for use by physicians and healthcare providers.
Features
- Proprietary technology platforms for identifying and validating drug targets based on human genetic data
- Expertise in siRNA-based therapeutics and capabilities in other therapeutic modalities
- Pipeline of differentiated clinical and preclinical programs for common diseases
- Focus on replicating beneficial genetic variants to improve health outcomes